RNA sequencing for tumor-initiating stem-like cells (TICs) treated with all-trans retinoic acid (ATRA) and suberoylanilide hydroxamic acid (SAHA)

TIC population plays a vital role for tumor recurrence and therapy resistnace. In this study, we identified the drug combination of ATRA and SAHA can specifically target TICs in vitro and in vivo. By conducting RNA sequencing and genome-wide transcriptome analysis, we comprehesively illustrate that the combination treatment epigenetically regulates TICs. Overall design: The TICs were treated with 5ug/ml of ATRA, 0.5ug/ml of SAHA or both for RNA sequencing by using Illumina HiSeq2500 system.